Oncology

Treg cells
#Amsterdam University Medical Centre #KRAS #Lung cancer #Oncology #The Francis Crick Institute #Tregs

Tregs block immune response in lung cancer, study finds

Researchers at the Francis Crick Institute, working with the Amsterdam University Medical Centre, have found that immune cells are held back from fighting lung tumours by another type of cell. Drugs that block a cancer-causing protein called KRAS-G12C are approved for use in lung cancer but… Read More

#Cancer Research #News

#Artificial intelligence (AI) #Cancer research #Immunotherpy #Oncology #Radiopharmaceuticals #Therapeutic Antibodies

What lies ahead in cancer research?

Megan Thomas comments and speaks with experts to uncover the future of cancer research. Artificial intelligence (AI) It’s not whether AI should be used, it’s when and how. Until several hurdles are overcome, such as data quality, data privacy and security, as well as regulatory and ethical challenges, this is… Read More

#Cancer Research #Exclusive Content

Antibodies
#Immunotherapy #Interview #Monoclonal antibodies #Oncology #Therapeutic Antibodies

The new wave: Creating next-gen antibody therapies

Diana Spencer speaks to Dr Wansu Qiu, Technical Account Manager at Sino Biological US, about how advances in engineering technologies are paving the way for improved antibody drugs. DS: Since 1986, the FDA has granted marketing authorisation to over 100 therapeutic antibodies, many in oncology. Why has this been a… Read More

#Exclusive Content #Opinion

#Financing #Oncology #Radioligand Therapies (RLTs) #Radiopharmaceuticals #Starget Pharma #Start-ups

Starget secures $5.1m for clinical trial of targeted cancer therapy

Start-up Starget Pharma has raised $5.1 million in funding to support development of its radioligand-based therapies that target tumour cells with focused radiation. The investment was secured from Cancer Focus, a fund established in collaboration with the MD Anderson Cancer Center at the University of Texas. Read More

#Business & Investment #News #Start-up Zone

#Career #Immuno-oncology #Oncology #Recruitment

Building an immuno-oncology talent pipeline

Jamie Gould, Consultant at The RSA Group, explores the talent landscape of the immuno-oncology sector. Immuno-oncology harnesses the power of the body’s immune system to fight cancer. This exciting field is rapidly evolving and already delivering a revolution in cancer therapeutics with a steady stream of recent approvals. In June… Read More

#Business & Investment #Exclusive Content

Human cells
#Drug delivery #Genomics #Oncology #Personalised medicine #Spatial biology

The opportunity for spatial biology in drug discovery  

DDW Editor Reece Armstrong speaks to Ellie Mahjubi, Vice President, Protein and cell analysis at Thermo Fisher Scientific, about how spatial biology is impacting drug discovery and development research.   RA: What’s the future and potential for spatial biology?  EM: Technological advancements in spatial… Read More

#Exclusive Content

Ovarian cancer cells
#Genetics / genomics #Icahn School of Medicine #Immunotherapy #Oncology #Ovarian cancer

Study paves way for improved immunotherapy for ovarian cancer

Researchers have discovered that an eczema-linked protein helps ovarian cancer manipulate its environment to resist immunotherapy, suggesting the potential for a skin drug-based treatment. Scientists at the Icahn School of Medicine at Mount Sinai used spatial genomics technology and preclinical animal models, with tumour specimens from… Read More

#Cancer Research #Editor's Choice #News

CAR-T cell therapy
#CAR-T #Cell therapy #Financing #Fundraising #Haematology #March Biosciences #Oncology

March Bio raises $28.4m for autologous CAR-T therapy

Biotechnology company March Biosciences (March Bio) has announced the close of a $28.4 million oversubscribed Series A financing, having raised over $51 million to date. Mission BioCapital and 4BIO Capital led the financing, with participation from KdT Ventures, Alexandria Venture Investments, Volnay Therapeutics, Modi Ventures, and… Read More

#Business & Investment #News

Radioactive containers
#Affibody #Nuclear medicine #Oncology #Preclinical investigations #Radiopharmaceuticals

Preclinical data shows efficacy of radio-therapeutic anti-HER2 agent

Affibody has shared the results of preclinical studies with its radiotherapeutic agent 177Lu-ABY-271 for treatment of HER2-expressing metastatic disease. The data were presented at the Annual Congress of the European Association of Nuclear Medicine by investigator Yongsheng Liu in the Professor Tolmachev group, Uppsala University. Read More

#Cancer Research #News

Non-small cell lung cancer
#Lung cancer #Monoclonal antibodies #Oncology #Phase I trial #Pierre Fabre

Trial assesses new approach to NSCLC with MET alterations

The first patient has been dosed with PFL-002/VERT-002 in a Phase I/II first-in-human trial for patients with non-small cell lung cancer (NSCLC) with MET alterations. PFL-002/VERT-002 is a monoclonal antibody acting as a degrader of c-MET. MET, also known as hepatocyte growth factor receptor… Read More

#Cancer Research #News

Monoclonal antibody
#Cancer Research UK #Clinical trial #Monoclonal antibodies #Oncology #UCB

Monoclonal antibody targets HLA-G in advanced cancers

A new clinical trial has launched to assess monoclonal antibody UCB4594 in people with advanced cancers. The first site for the study has opened at the National Institute for Health and Care Research (NIHR) Manchester Clinical Research Facility (CRF) at The Christie NHS Foundation Trust (The… Read More

#Cancer Research #News

Cancer research in laboratory
#Breast cancer #Drug approvals #Drug discovery #Oncology

Early breast cancer drug Kisqali gets EU recommendation 

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended granting marketing authorisation for Novartis’ Kisqali (ribociclib).  The positive opinion relates to the adjuvant treatment of adults with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) early breast cancer (EBC),… Read More

#Cancer Research #News

#Biopharma #Drug development #Drug discovery #Oncology #Partnership

Sanofi and Orano invest in potential of radioligand cancer medicines 

Sanofi and Orano Med have entered into an agreement with the aim of accelerating the development of radioligand medicines.  Building on the radioligand pipeline of Orano Med, Sanofi and Orano will invest in a new entity, operating under the Orano Med brand.  The new entity… Read More

#News

Pancreatic cancer
#Oncology #Panavance Therapeutics #Pancreatic cancer #Phase I trial

Interim data reveals potential of new pancreatic cancer drug

Misetionamide (GP-2250) in combination with gemcitabine has demonstrated a good safety profile and potential therapeutic benefit in the treatment of pancreatic adenocarcinoma. Panavance Therapeutics revealed the interim data from its Phase I clinical study at the 2024 Visceral Medicine Congress in Leipzig, Germany. The… Read More

#Cancer Research #News